Ocugen Receives FDA Orphan Drug Designation for OCU300 (Brimonidine Tartrate) for the Treatment of Ocular Graft Versus Host Disease
Wednesday, August 09, 2017 | FDA Approval/Clearance
Ocugen announced that the FDA has granted orphan drug designation for OCU300 (brimonidine tartrate) for the treatment of ocular graft versus host disease (oGVHD). Ocular GVHD is a common complication that occurs in 40-60 percent of patients who have undergone allergenic hematological stem cell transplantation (allo-SCT) or bone marrow transplants. Driven by autoimmune inflammation, oGVHD induces severe ocular surface disease, which over time significantly diminishes quality of life, and restricts daily activities due to visual impairment.
"We are very excited to receive the first ever orphan drug designation by the FDA for oGVHD, emphasizing the unmet medical need for patients with this disease. This is a significant milestone that will allow us to further advance the clinical development of OCU300, with a proprietary nanoemulsion, into a phase 3 clinical trial in the near future," Shankar Musunuri, PhD, MBA, chairman, CEO and co-founder of Ocugen, said in a company news release.
Ocugen executed an exclusive worldwide license agreement for OCU300 with the University of Illinois at Chicago last year. Dr. Sandeep Jain, Director of the ocular GVHD Clinic at the University of Illinois at Chicago and an inventor of OCU300 for the treatment of oGVHD, said, "I'm pleased that Ocugen has received orphan drug designation for oGVHD. This is a debilitating condition for which no approved pharmaceutical therapeutics exist."
The FDA Office of Orphan Products Development grants orphan designation for novel drugs or biological that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. Orphan designation qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including 7-year period of U.S. Marketing exclusivity, tax credits for clinical research costs, clinical research trial design assistance, the ability to apply for annual grant funding, and waiver of Prescription Drug User Fee Act (PDUFA) for filing fees.
You must be logged in to leave a comment.